Vardhaman Laboratories Peer Comparison

BSE: 524796

₹0.51

₹0.02 (4.08%)

As on 16-Aug-2019IST

Market cap

₹0 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

0.1

Div. Yield

0 %

Edit

	Vardhaman Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	0	32,416	30,013	28,857	26,633
Revenue (₹ Cr)	--	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-0.02	414.00	288.22	-371.81	387.35
Net Margin (%)	-383.33	11.23	14.79	-3.93	26.01
RoE (%)	-1.15	8.38	29.77	-3.85	25.18
Price to Earnings	--	79.26	104.14	--	68.96
Price-To-Book	0.11	6.44	22.36	3.60	15.41

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Vardhaman Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	0.00	3,936.90	65.18	--	188.22
Total Income	0.04	4,114.39	69.48	--	191.18
Total Expenditure	0.08	3,992.33	60.56	--	157.70
EBITDA	-0.08	-55.43	4.63	--	30.52
Depreciation	--	149.53	6.27	--	1.91
EBIT	-0.08	-204.96	-1.64	--	28.62
Interest	0.00	255.49	2.16	--	3.23
Other Income	0.04	177.49	4.29	--	2.96
Exceptional Items	--	-358.19	--	--	--
Profit before Tax	-0.04	-641.15	0.49	--	28.35
Provision for Tax	--	25.70	0.28	--	9.85
Profit after Tax	-0.04	-666.85	0.21	--	18.50

Liabilities (₹ Cr)

	Vardhaman Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	2.00	2,852.15	178.44	--	57.68
Minority Interest	--	345.73	--	--	--
Non-Current Liabilities	0.00	2,088.89	14.20	--	32.73
Current Liabilities	0.03	2,691.71	34.62	--	65.00
Total Liabilities	2.03	8,127.59	227.25	--	155.45

Assets (₹ Cr)

	Vardhaman Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	0.00	4,598.88	73.08	--	66.45
Current Assets	2.03	3,379.60	154.17	--	87.20
Total Assets	2.03	8,127.59	227.25	--	155.45
Total Debt*	0.00	3,747.82	29.82	--	43.83
Net Current Assets	2.00	687.89	119.55	--	22.19
Contingent Liabilities	--	576.12	--	--	--

Cashflow (₹ Cr)

	Vardhaman Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	0.02	68.44	-16.11	--	8.46
Cash Flow from Investing Activities	--	630.24	19.72	--	-25.32
Cash from Financing Activities	-0.08	-769.47	-2.53	--	14.62
Net Cash Inflow / Outflow	-0.06	-70.79	1.08	--	-2.23

Ratios

Profitability Ratios

	Vardhaman Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-1.98	-5.47	1.27	--	38.24
ROE (%)	-1.98	-21.81	0.12	--	39.03
ROA (%)	-1.96	-7.93	0.09	--	13.99
EBIT Margin (%)	--	3.10	13.68	--	17.79
Net Margin (%)	-113.14	-16.21	0.31	--	9.67
Cash Profit Margin (%)	--	-13.14	9.94	--	10.84

Growth Ratios

	Vardhaman Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	--	-1.94	0.00	--	17.45
EBIT Growth (%)	-10.63	-3.93	-8.67	--	43.40
Net Profit Growth (%)	-7.75	-195.01	0.00	--	53.51
EPS Growth (%)	-7.79	-210.52	0.00	--	54.05
Book Value Growth (%)	-1.97	-14.68	0.00	--	43.84

Valuation Ratios

	Vardhaman Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	0.00	0.00	--	0.00
Price / Book Value	0.14	2.85	0.00	--	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	3.82	87.67	3.50	--	1.32
Market Cap (₹ Cr)	--	8,035.78	0.00	--	0.00

Solvency Ratios

	Vardhaman Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.00	1.33	0.17	--	0.78
Short term debt to equity ratio	--	0.15	0.08	--	0.16
Current Ratio	70.12	1.26	4.45	--	1.34
Quick Ratio	70.12	0.94	4.05	--	0.92
Interest Coverage	-1,740.70	-1.51	1.23	--	9.79

Operating Efficiency Ratios

	Vardhaman Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	--	24.45	57.13	--	26.55
Asset Turnover	0.00	0.47	0.29	--	1.42
Receivable days	--	92.57	208.51	--	83.83
Inventory Days	--	91.03	78.67	--	45.68
Payable days	--	115.29	264.75	--	139.26
Cash Conversion Cycle	--	68.30	22.43	--	-9.76

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly